[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of Humira®
(Adalimumab) in Pediatric Patients with Moderately to Severely Active Crohn's Disease (CD) – CAPE

What is the purpose of the study? (in Layman's terms, please describe the study)

The purpose of this study is to collect long term safety information on Humira® (adalimumab), a monoclonal antibody approved for the treatment of Crohn’s Disease in children.

Upstate Institutional Review Board (IRB) Number:

789684

Study/Protocol ID:

P11-292

Study Phase:

N/A

Patient Age Group:

Children

Principal Investigator:

Prateek D Wali

Who can I contact for more information?

Name: Sharihan Amra
Phone: 315-464-8444
Email: amras@upstate.edu

Return to Previous Page || Search Again

Top